Early recognition and prompt initiation of factor VIII inhibitor bypassing therapy (e.g., recombinant activated factor VII (rFVIIa), activated prothrombin complex concentrate (FEIBA)) and immunosuppressive treatment (e.g., corticosteroids, cyclophosphamide, rituximab) are critical in reducing mortality in AHA [3,6]. This evidence concerns the gene F7 and autoimmune hemolytic anemia.